Combined Therapeutics is dedicated to creating safer and more efficacious immunotherapies and vaccines for cancer and infectious diseases. They use their mRNA platform to specifically target therapeutic protein expression, while minimizing off-target effects. Their science involves a therapeutic mRNA modified to include a binding miRNA sequence, encapsulated in a lipid nanoparticle. Advantages of their platform include needing a lower vaccine dose, lengthening vaccine durability, and restricting expression to targeted tissues. Combined Therapeutics was founded in 2016, based in Boston, with international operations in London and Paris.

Combined Therapeutics

Making Safer and More Effective Vaccines with Targeted mRNA

Combined Therapeutics to Present its Next-Generation mRNA-Based Vaccine Platform at the World Vaccine Congress 2023

Using mRNA Vaccines to Effectively and Safely Target Infectious Disease and Cancer with Dr. Thomas VanCott and Dr. Romain Micol Combined Therapeutics

mRNA Vaccine Platforms With Combined Therapeutics’ Dr. Romain Micol


              Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70
            

mRNA Vaccines

Biotech Is Back With Allan Shaw - Life Science Leader Magazine

Cancer Vaccines Clinical Trial Pipeline Analysis - GlobeNewswire

Killing three parasites with one stone - Chemistry World

"Creating the next generation of mRNA vaccines" - Thank you to Science Magazine / AAAS for highlighting our work, to tailor mRNA vaccines for vulnerable populations and advance adjuvant innovation, on the Cover of this week's issue of #ScienceTranslationalMedicine! - https://lnkd.in/etmfCXgk -

On the Cover - "An Adjuvant Advance": 
- To improve immune durability, we adjuvanted the BNT162b2 SARS-CoV-2 vaccine with a mRNA encoding IL-12p70, which amplified vaccine responses even at very low vaccine doses.
- The team also developed a strategy to limit expression of the mRNAs to muscle, potentially reducing systemic reactogenicity after vaccination.
- Overall, we prove that mRNA vaccines, like their protein counterparts, highly benefit from adjuvantation.

Led by the fantastic team of Byron Brook, Valerie D. and Romain Micol - 
Combined Therapeutics, Precision Vaccines Program, Boston Children's Hospital and Harvard Medical School. We appreciate the support from the National Institute of Allergy and Infectious Diseases (NIAID).

Published now in the journal of Science Translational Medicine! PVP researchers Byron Brook, David Dowling, Ph.D., and Ofer Levy, MD PhD along with Valerie Duval and Romain Micol from Combined Therapeutics discover a novel adjuvant system called IL-12 MOP and highlight its importance in #mRNA vaccine technology, capable of increasing its durability and effectiveness. Read the full article here: https://lnkd.in/eTThbX9Q

Hybrid Graphene-Gold Nanoparticle-Based Nucleic Acid Conjugates for Cancer-Specific Multimodal Imaging and Combined Therapeutics - Wiley Online Library

Combined Therapeutics Granted Patent for its mRNA Vaccine Platform by USPTO

Multifunctional nanoparticle-mediated combining therapy for human diseases - Nature.com

Vaccine-based protection from COVID-19 wanes over time, especially in older adults. To address this problem, NIAID-supported researchers added mRNA encoding immune protein IL-12 to a COVID-19 mRNA vaccine, raising immune responses in aged mice to levels akin to those seen in young adult mice. IL-12 is important for responding well to vaccination, but natural production of this protein declines as people and mice age. For safety, researchers designed the adjuvant so only the muscle where it is injected makes the protein. These findings could mark a step toward better COVID-19 mRNA vaccines for older adults. Learn more: https://lnkd.in/eTThbX9Q

#NIH #NIAID #COVID19 #mRNA #immunology #science #research #ScienceTranslationalMedicine

Boston Children's Hospital 
Brigham and Women's Hospital 
Combined Therapeutics 



              Rice Biotech Launch Pad adds pharmaceuticals pioneer Robert Ruffolo to external advisory board
            

 Combined Therapeutics Wins $250,000 MilliporeSigma Advance Biotech Grant 

Combined Therapeutics to Present at 11th International mRNA Health Conference

Combined Therapeutics Expands Board of Directors with Appointments of Biopharma Industry Veterans Paul Wotton, Robert Ruffolo and Kevin F. McLaughlin

 Combined Therapeutics Granted Patent for its mRNA Vaccine Platform by USPTO 

Combined Therapeutics is presenting at #BiotechShowcase! Join us in San Francisco this January 8–10, 2024 to attend our presentation. 

Register now to meet one-to-one: biotechshowcase.com 

Thomas VanCott, Ph.D., Combined Therapeutics’ CSO, will be presenting on January 8 at 9:30 a. m. 

What You Need to Know About Combined Therapeutics mRNA-Based Vaccine Platform

🌟 Next up we welcomed Derek O'Hagan, Senior Advisor R&D at GSK, who presented on ‘The Role of Adjuvants in Vaccine Development.’

Derek provided a comprehensive review of the mechanisms and science behind adjuvants, discussing how they enhance immune responses and their potential to improve the performance of RNA vaccines. 💉✨ 

He also shared insights into the future outlook, exploring what the next generation of adjuvants might look like. We look forward to continued discussions on this vital topic!

#mRNA #Vaccines #Adjuvants #Immunology #Innovation #Biotech #GSK

Excellos Announces Acceleration of Commercialization, New CEO - Business Wire

Combined Therapeutics CEO, Romain Micol, to Present at the World Vaccine Congress Europe 2023


              Biomedical scientist Robert Langer receives the 2023 Dr. Paul Janssen Award for Biomedical Research
            

A shot in the arm for mRNA vaccines? - Boston Children's Discoveries

Our work highlighted by the NIH!

Combined Therapeutics

Business:

About: